NCT01666964

Brief Summary

We would like to ascertain the prevalence of hypopituitarism after combat-related TBI. This will lead to enhanced awareness, recognition, and treatment of hypopituitarism, which can have life-saving ramifications and enhance quality of life and rehabilitation efforts in our combat veterans.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2012

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 14, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 16, 2012

Completed
2 months until next milestone

Study Start

First participant enrolled

October 1, 2012

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2014

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2015

Completed
Last Updated

August 16, 2012

Status Verified

August 1, 2012

Enrollment Period

2.2 years

First QC Date

August 14, 2012

Last Update Submit

August 14, 2012

Conditions

Keywords

Traumatic brain injuryhypopituitarism

Outcome Measures

Primary Outcomes (1)

  • Prevalence of anterior pituitary dysfunction

    Pituitary screening blood tests: cortisol, follicle stimulating hormone, luteinizing hormone, total testosterone (males) or estradiol (females), thyrotropin, free thyroxine, prolactin, insulin-like growth factor-1. Growth-hormone deficiency will be confirmed with a glucagon stimulation test. Adrenal Insufficiency will be confirmed with an Cosyntropin stimulation test.

    at 3 (+/- 15 days) and 6 months (+/- 15 days)

Secondary Outcomes (1)

  • Prevalence of posterior pituitary dysfunction

    at 3 and 6 months

Other Outcomes (2)

  • Background prevalence of hypopituitarism in a military population using the Department of Defense serum repository

    At completion of Enrollment

  • Relationship between hypopituitarism secondary to combat-related TBI and symptom scores using the Neurobehavioral Symptom Index.

    3 and 6 months post-injury

Study Arms (2)

3 months post-injury

Male and female combat veterans age 18 years and older with the diagnosis of Traumatic Brain Injury caused by a blast that occurred 3 months prior to enrollment, 50% mild, 50% moderate and severe

Other: Blast Traumatic Brain Injury

6 months post-injury

Male and female combat veterans age 18 years and older with the diagnosis of Traumatic Brain Injury caused by a blast that occurred 6 months prior to enrollment, 50% mild, 50% moderate and severe

Other: Blast Traumatic Brain Injury

Interventions

Exposure during combat to blast-wave mediated Traumatic Brain Injury

Also known as: bTBI
3 months post-injury6 months post-injury

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Male and female combat veterans age 18 years and older with the diagnosis of Traumatic Brain Injury that occurred 3 and 6 months prior to enrollment.

You may qualify if:

  • Combat veterans who are 3 or 6 months post combat-related TBI and age 18yrs or older
  • Must demonstrate capacity for informed consent
  • Must be DEERS eligible (Military healthcare beneficiary)

You may not qualify if:

  • Pregnancy (to be assessed by urine HCG)
  • Use of hormonal contraceptives
  • Chronic oral or intravenous glucocorticoids
  • Use of hormonal therapy to include estrogen and testosterone
  • Prior diagnosis of hypopituitarism prior to combat related TBI

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Walter Reed National Military Medical Center

Bethesda, Maryland, 20889, United States

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

No specimens will be stored. Blood Testing: Testosterone 2ml Estradiol 2ml LH/FSH 3ml Prolactin 2ml IGF-1 1ml TSH 2ml Free T4 1ml Sodium 2ml Total blood for cosyntropin stim test 9ml Total blood for glucagon stim test 15ml Water deprivation testing 12ml-32ml Urine Testing: HCG 2ml Water deprivation testing 8ml-18ml

MeSH Terms

Conditions

Brain Injuries, TraumaticHypopituitarism

Condition Hierarchy (Ancestors)

Brain InjuriesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesCraniocerebral TraumaTrauma, Nervous SystemWounds and InjuriesPituitary DiseasesHypothalamic DiseasesEndocrine System Diseases

Study Officials

  • Andrew J. Brackbill, M.D.

    WalterReed National Military Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Andrew J Brackbill, M.D.

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
FED
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 14, 2012

First Posted

August 16, 2012

Study Start

October 1, 2012

Primary Completion

December 1, 2014

Study Completion

May 1, 2015

Last Updated

August 16, 2012

Record last verified: 2012-08

Locations